The therapeutic effect of CD47 blockade as a cancer treatment relies more on dendritic cells than macrophages, scientists report. Anti-CD47-mediated tumor rejection will require both innate and adaptive responses.
The therapeutic effect of CD47 blockade as a cancer treatment relies more on dendritic cells than macrophages, scientists report. Anti-CD47-mediated tumor rejection will require both innate and adaptive responses.